Huvepharma, a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products has agreed to acquire certain assets from Zoetis, LLC.

This includes products, and two owned and one leased manufacturing sites in the USA.  The assets associated with this deal involve an international portfolio of medicated feed additives, including Albac (excluding the USA market) and bio-Cox/Salinomax as well as Inovocox, leading coccidiosis vaccine for broilers. 

Along with these products, Huvepharma will acquire manufacturing sites in the US located in Laurinburg, North Carolina and Van Buren, Arkansas.

Other assets included in the acquisition are water soluble veterinary products brands R-Pen, Oxytet, Sul-Q-Nox, CTC, Lincomycin, Poultry Sulfa and Neo-Sol including the formulation facility located in Longmont, Colorado. 

Additional pharmaceuticals assets were also acquired that are predominately sold in Europe, Huvepharma said in a statement that added that employees at the three manufacturing sites will be transferred to the company.

“This acquisition from Zoetis reinforces and builds upon our commitment to our customers in providing high quality products for livestock, produced in our EU and USA based facilities. The brands associated with these assets will continue to strengthen our position in key markets and reinforce our growth potential, Kiril Domuschiev, President and owner of Huvepharma, said.

Products are expected to be available from Huvepharma on February 1, 2016 and may continue to be ordered from Zoetis prior to that.

O P Singh, Managing Director, Huvepharma SEA added, “This acquisition will strengthen the existing portfolio of products in a big way. Huvepharma SEA has plans for major expansion and scale up of operations in the region.”

Huvepharma is a privately owned, global animal health company with headquarters in Sofia, Bulgaria that brands a broad portfolio of products used in swine, poultry and cattle production. 

Published on December 24, 2015